{"product_id":"nexgard-spectra-s-3-5-7-5-kg-3-comprimate","title":"Nexgard Spectra S (3.5 - 7.5 kg), 3 tablets","description":"\u003cdiv class=\"std\"\u003e\n\u003cp\u003e\u003cstrong\u003eQUALITATIVE AND QUANTITATIVE COMPOSITION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp align=\"left\"\u003eEach chewable tablet contains:\u003c\/p\u003e\n\u003cp align=\"left\"\u003e\u003cstrong\u003eActive substances:\u003c\/strong\u003e\u003c\/p\u003e\n\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"0\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"319\"\u003e\n\u003cp align=\"center\"\u003eNEXGARD SPECTRA\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd valign=\"top\" width=\"113\"\u003e\n\u003cp align=\"center\"\u003eAfoxolaner\u003c\/p\u003e\n\u003cp align=\"center\"\u003e(mg)\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd valign=\"top\" width=\"132\"\u003e\n\u003cp align=\"center\"\u003eMilbemycin oxime (mg)\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"319\"\u003echewable tablets for dogs weighing 3.5-7.5 kg\u003c\/td\u003e\n\u003ctd valign=\"top\" width=\"113\"\u003e18.75\u003c\/td\u003e\n\u003ctd valign=\"top\" width=\"132\"\u003e3.75\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003ePHARMACEUTICAL FORM\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eChewable tablets.\u003c\/p\u003e\n\u003cp align=\"left\"\u003eRed to reddish-brown mottled, round (tablets for dogs weighing 2-3.5 kg) or rectangular (tablets for dogs weighing \u003e 3.5-7.5 kg, tablets for dogs weighing \u003e 7.5-15 kg, tablets for dogs weighing \u003e 15-30 kg, and tablets for dogs weighing \u003e 30-60 kg) tablets.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCLINICAL PARTICULARS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eTarget species: \u003c\/strong\u003eDogs\u003c\/p\u003e\n\u003cp align=\"left\"\u003e\u003cstrong\u003eIndications for use, specifying the target species\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp align=\"left\"\u003eFor the treatment of flea and tick infestations in dogs when concurrent prevention of heartworm disease and\/or treatment of gastrointestinal nematode infestations is indicated.\u003c\/p\u003e\n\u003cp align=\"left\"\u003eTreatment of flea infestations (\u003cem\u003eCtenocephalides felis\u003c\/em\u003e and \u003cem\u003eC. canis\u003c\/em\u003e) in dogs for 5 weeks. Treatment of tick infestations (\u003cem\u003eDermacentor reticulatus, Ixodes ricinus, Rhipicephalus sanguineus\u003c\/em\u003e) in dogs for 4 weeks.\u003c\/p\u003e\n\u003cp align=\"left\"\u003eFleas and ticks must attach to the host and commence feeding to be exposed to the active substance.\u003c\/p\u003e\n\u003cp align=\"left\"\u003eTreatment of adult gastrointestinal nematode infestations of the following species: roundworms (\u003cem\u003eToxocara canis \u003c\/em\u003eand \u003cem\u003eToxocara leonina\u003c\/em\u003e), hookworms (\u003cem\u003eAncyclostoma caninum \u003c\/em\u003eand \u003cem\u003eAncyclostoma braziliense\u003c\/em\u003e) and whipworms (\u003cem\u003eTrichuris vulpis\u003c\/em\u003e).\u003c\/p\u003e\n\u003cp\u003ePrevention of heartworm disease (\u003cem\u003eDirofilaria immitis \u003c\/em\u003elarval stage) if administered monthly.\u003c\/p\u003e\n\u003cp align=\"left\"\u003e\u003cstrong\u003eContraindications: \u003c\/strong\u003eDo not use in cases of hypersensitivity to the active substances or to any of the excipients.\u003c\/p\u003e\n\u003cp align=\"left\"\u003e\u003cstrong\u003e \u003c\/strong\u003e\u003c\/p\u003e\n\u003cp align=\"left\"\u003e\u003cstrong\u003eSpecial warnings for each target species\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp align=\"left\"\u003eParasites must commence feeding on the host to be exposed to afoxolaner; therefore, the risk of transmission of infectious diseases cannot be excluded.\u003c\/p\u003e\n\u003cp align=\"left\"\u003eResistance of parasites to a particular class of antiparasitic medicinal product may develop following frequent use of a compound from that class. Therefore, the use of this product should be based on an assessment of each individual case and on local epidemiological information about the current susceptibility of the target species to limit the possibility of future selection for resistance.\u003c\/p\u003e\n\u003cp align=\"left\"\u003eMaintaining the efficacy of macrocyclic lactones is essential for the control of \u003cem\u003eDirofilaria immitis\u003c\/em\u003e. To minimise the risk of resistance selection, it is recommended to test dogs for circulating antigens and blood microfilariae at the start of each preventative treatment period.\u003c\/p\u003e\n\u003cp align=\"left\"\u003eOnly negative animals should be treated.\u003c\/p\u003e\n\u003cp align=\"left\"\u003e\u003cstrong\u003eSpecial precautions for use\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp align=\"left\"\u003eSpecial precautions for use in animals\u003c\/p\u003e\n\u003cp align=\"left\"\u003eIn the absence of available data, treatment of puppies younger than 8 weeks of age and\/or dogs weighing less than 2 kg should only be carried out based on a risk\/benefit assessment by the veterinarian.\u003c\/p\u003e\n\u003cp align=\"left\"\u003eDogs living in heartworm endemic areas should be tested for adult heartworm infestation before administration of NEXGARD SPECTRA. Infested dogs should be treated with an adulticide at the discretion of the veterinarian to eliminate adult heartworms. NEXGARD SPECTRA is not indicated for the elimination of microfilariae.\u003c\/p\u003e\n\u003cp align=\"left\"\u003eThe recommended dose must be strictly followed in Collie dogs or other related breeds.\u003c\/p\u003e\n\u003cp align=\"left\"\u003eSpecial precautions to be taken by the person administering the veterinary medicinal product to animals\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThis product may cause gastrointestinal disturbances if ingested.\u003c\/li\u003e\n\u003cli\u003eKeep tablets in blisters and the blister in the carton until use.\u003c\/li\u003e\n\u003cli\u003eIn case of accidental ingestion, especially by children, seek medical advice immediately and show the product label to the physician.\u003c\/li\u003e\n\u003cli\u003eWash hands after use.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp align=\"left\"\u003e\u003cstrong\u003eAdverse reactions (frequency and seriousness)\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp align=\"left\"\u003eIn clinical studies, no serious adverse reactions were attributed to the combination of afoxolaner and milbemycin oxime. Infrequent reactions such as vomiting, diarrhoea, lethargy, anorexia, and pruritus were observed. These reactions generally resolved spontaneously and were of short duration.\u003c\/p\u003e\n\u003cp align=\"left\"\u003eThe frequency of adverse reactions is defined using the following convention:\u003c\/p\u003e\n\u003cp align=\"left\"\u003e- Very common (more than 1 in 10 animals displaying adverse reactions during the course of one treatment)\u003c\/p\u003e\n\u003cp align=\"left\"\u003e- Common (more than 1 but less than 10 animals in 100 animals)\u003c\/p\u003e\n\u003cp align=\"left\"\u003e- Uncommon (more than 1 but less than 10 animals in 1,000 animals)\u003c\/p\u003e\n\u003cp align=\"left\"\u003e- Rare (more than 1 but less than 10 animals in 10,000 animals)\u003c\/p\u003e\n\u003cp align=\"left\"\u003e- Very rare (less than 1 animal in 10,000 animals, including isolated reports).\u003c\/p\u003e\n\u003cp align=\"left\"\u003e\u003cstrong\u003eUse during pregnancy, lactation or lay\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp align=\"left\"\u003eLaboratory studies conducted on rats and rabbits have not shown any teratogenic effects or any negative effect on the reproductive capacity of males and females. The safety of the veterinary medicinal product has not been established during pregnancy and lactation or for breeding dogs. Use only according to the benefit-risk assessment by the veterinarian.\u003c\/p\u003e\n\u003cp align=\"left\"\u003e\u003cstrong\u003eInteractions with other medicinal products and other forms of interaction\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp align=\"left\"\u003eMilbemycin oxime is a substrate of P-glycoprotein (P-gp), thus it may interact with other P-gp substrates (e.g., digoxin, doxorubicin) or other macrocyclic lactones. Therefore, concomitant treatment with other P-gp substrates may lead to increased toxicity.\u003c\/p\u003e\n\u003cp align=\"left\"\u003e\u003cstrong\u003eAmounts to be administered and administration route\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp align=\"left\"\u003eFor oral administration.\u003c\/p\u003e\n\u003cp align=\"left\"\u003eDosage:\u003c\/p\u003e\n\u003cp align=\"left\"\u003eThe product should be administered at a dose of 2.50-5.36 mg\/kg afoxolaner and 0.50-1.07 mg\/kg milbemycin oxime body weight according to the following table:\u003c\/p\u003e\n\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"0\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd rowspan=\"2\" valign=\"top\" width=\"97\"\u003e\u003cstrong\u003eDog weight (kg)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd colspan=\"5\" valign=\"top\" width=\"522\"\u003e\u003cstrong\u003eConcentration and number of chewable tablets to be administered\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"102\"\u003e\n\u003cp align=\"center\"\u003eNEXGARD SPECTRA\u003c\/p\u003e\n\u003cp align=\"center\"\u003e9 mg\/ 2 mg\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd valign=\"top\" width=\"96\"\u003e\n\u003cp align=\"center\"\u003eNEXGARD SPECTRA\u003c\/p\u003e\n\u003cp align=\"center\"\u003e19 mg\/ 4 mg\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd valign=\"top\" width=\"102\"\u003e\n\u003cp align=\"center\"\u003eNEXGARD SPECTRA\u003c\/p\u003e\n\u003cp align=\"center\"\u003e38 mg\/ 8 mg\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd valign=\"top\" width=\"102\"\u003e\n\u003cp align=\"center\"\u003eNEXGARD SPECTRA\u003c\/p\u003e\n\u003cp align=\"center\"\u003e75 mg\/ 15 mg\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd valign=\"top\" width=\"120\"\u003e\n\u003cp align=\"center\"\u003eNEXGARD SPECTRA\u003c\/p\u003e\n\u003cp align=\"center\"\u003e150 mg\/ 30 mg\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"97\"\u003e\n\u003cp align=\"center\"\u003e2-3.5\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd valign=\"top\" width=\"102\"\u003e\n\u003cp align=\"center\"\u003e1\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd valign=\"top\" width=\"96\"\u003e\n\u003cp align=\"center\"\u003e\n\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd valign=\"top\" width=\"102\"\u003e\n\u003cp align=\"center\"\u003e\n\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd valign=\"top\" width=\"102\"\u003e\n\u003cp align=\"center\"\u003e\n\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd valign=\"top\" width=\"120\"\u003e\n\u003cp align=\"center\"\u003e\n\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"97\"\u003e\n\u003cp align=\"center\"\u003e\u0026gt;3.5-7.5\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd valign=\"top\" width=\"102\"\u003e\n\u003cp align=\"center\"\u003e\n\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd valign=\"top\" width=\"96\"\u003e\n\u003cp align=\"center\"\u003e1\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd valign=\"top\" width=\"102\"\u003e\n\u003cp align=\"center\"\u003e\n\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd valign=\"top\" width=\"102\"\u003e\n\u003cp align=\"center\"\u003e\n\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd valign=\"top\" width=\"120\"\u003e\n\u003cp align=\"center\"\u003e\n\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"97\"\u003e\n\u003cp align=\"center\"\u003e\u0026gt;7.5-15\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd valign=\"top\" width=\"102\"\u003e\n\u003cp align=\"center\"\u003e\n\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd valign=\"top\" width=\"96\"\u003e\n\u003cp align=\"center\"\u003e\n\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd valign=\"top\" width=\"102\"\u003e\n\u003cp align=\"center\"\u003e1\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd valign=\"top\" width=\"102\"\u003e\n\u003cp align=\"center\"\u003e\n\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd valign=\"top\" width=\"120\"\u003e\n\u003cp align=\"center\"\u003e\n\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"97\"\u003e\n\u003cp align=\"center\"\u003e\u0026gt;15-30\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd valign=\"top\" width=\"102\"\u003e\n\u003cp align=\"center\"\u003e\n\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd valign=\"top\" width=\"96\"\u003e\n\u003cp align=\"center\"\u003e\n\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd valign=\"top\" width=\"102\"\u003e\n\u003cp align=\"center\"\u003e\n\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd valign=\"top\" width=\"102\"\u003e\n\u003cp align=\"center\"\u003e1\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd valign=\"top\" width=\"120\"\u003e\n\u003cp align=\"center\"\u003e\n\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"97\"\u003e\n\u003cp align=\"center\"\u003e\u0026gt;30-60\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd valign=\"top\" width=\"102\"\u003e\n\u003cp align=\"center\"\u003e\n\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd valign=\"top\" width=\"96\"\u003e\n\u003cp align=\"center\"\u003e\n\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd valign=\"top\" width=\"102\"\u003e\n\u003cp align=\"center\"\u003e\n\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd valign=\"top\" width=\"102\"\u003e\n\u003cp align=\"center\"\u003e\n\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd valign=\"top\" width=\"120\"\u003e\n\u003cp align=\"center\"\u003e1\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp align=\"left\"\u003e For dogs over 60 kg body weight, the necessary combination of chewable tablets should be used.\u003c\/p\u003e\n\u003cp align=\"left\"\u003eMethod of administration:\u003c\/p\u003e\n\u003cp align=\"left\"\u003eThe tablets are chewable and palatable for most dogs. If the dog does not accept the tablets directly, they can be administered with food.\u003c\/p\u003e\n\u003cp align=\"left\"\u003eTreatment regimen:\u003c\/p\u003e\n\u003cp align=\"left\"\u003eThe treatment regimen should be based on the veterinary diagnosis and the local epidemiological situation.\u003c\/p\u003e\n\u003cp align=\"left\"\u003eNEXGARD SPECTRA can be used as seasonal preventative treatment against fleas and ticks (replacing treatment with a monovalent product acting only against fleas and ticks) in dogs concurrently infested with gastrointestinal nematodes. A single treatment is effective against gastrointestinal nematodes. After treating nematode infestations, treatment against flea and tick infestations can be continued by applying the monovalent product.\u003c\/p\u003e\n\u003cp align=\"left\"\u003e\u003cem\u003eDisease: Heartworm disease:\u003c\/em\u003e\u003c\/p\u003e\n\u003cp align=\"left\"\u003eNEXGARD SPECTRA kills \u003cem\u003eDirofilaria immitis \u003c\/em\u003elarvae for one month after their transmission by mosquitoes, therefore the product must be administered at regular monthly intervals throughout the vector-prone periods, starting from the month after the first exposure to mosquitoes. Treatment should continue until one month after the last exposure to mosquitoes. To establish a treatment routine, it is recommended to administer the treatment on the same day of the month.\u003c\/p\u003e\n\u003cp align=\"left\"\u003eIf replacing another heartworm prevention product, the first treatment with NEXGARD SPECTRA should start on the day the previous medication was due to be administered.\u003c\/p\u003e\n\u003cp align=\"left\"\u003eDogs living in or having travelled to a heartworm endemic region may be infested with adult heartworms. No therapeutic effect against adult \u003cem\u003eDirofilaria immitis \u003c\/em\u003ehas been established. Therefore, it is recommended that all dogs 8 months of age or older living in heartworm endemic areas be tested for adult heartworm infestation before being treated with a heartworm prevention product.\u003c\/p\u003e\n\u003cp align=\"left\"\u003e\u003cstrong\u003e \u003c\/strong\u003e\u003c\/p\u003e\n\u003cp align=\"left\"\u003e\u003cstrong\u003eOverdose (symptoms, emergency procedures, antidotes), if applicable\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp align=\"left\"\u003eNo adverse reactions were observed in healthy puppies older than 8 weeks after 6 treatments with 5 times the maximum dose.\u003c\/p\u003e\n\u003cp align=\"left\"\u003e\u003cstrong\u003e \u003c\/strong\u003e\u003c\/p\u003e\n\u003cp align=\"left\"\u003e\u003cstrong\u003eWithdrawal periods: \u003c\/strong\u003eNot applicable.\u003c\/p\u003e\n\u003cp align=\"left\"\u003e\u003cstrong\u003ePHARMACOLOGICAL PROPERTIES\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp align=\"left\"\u003ePharmacotherapeutic group: antiparasitic products, endectocides, milbemycin combinations.\u003c\/p\u003e\n\u003cp align=\"left\"\u003eATC veterinary code: QP54AB51\u003c\/p\u003e\n\u003cp align=\"left\"\u003e\u003cstrong\u003e \u003c\/strong\u003e\u003c\/p\u003e\n\u003cp align=\"left\"\u003e\u003cstrong\u003ePharmacodynamic properties\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp align=\"left\"\u003eAfoxolaner:\u003c\/p\u003e\n\u003cp align=\"left\"\u003eAfoxolaner is an insecticide and acaricide belonging to the isoxazoline family.\u003c\/p\u003e\n\u003cp align=\"left\"\u003eAfoxolaner acts by interacting with chloride ion channels, primarily those with a binding site for the gamma-aminobutyric acid (GABA) neurotransmitter, thereby blocking pre- and post-synaptic chloride ion transfers across the cell membrane. This results in uncontrolled activity of the central nervous system and death of insects and mites. The selective toxicity of afoxolaner between insects\/mites and mammals is a consequence of the characteristic sensitivity of insect\/mite GABA receptors versus those of mammals.\u003c\/p\u003e\n\u003cp align=\"left\"\u003eAfoxolaner is active against adult fleas as well as some tick species such as \u003cem\u003eRhipicephalus sanguineus, Dermacentor reticulatus \u003c\/em\u003eand \u003cem\u003eD. variabilis, Ixodes ricinus \u003c\/em\u003eand \u003cem\u003eI. scapularis, Amblyomma americanum \u003c\/em\u003eand \u003cem\u003eHaemaphysalis longicornis.\u003c\/em\u003e\u003c\/p\u003e\n\u003cp align=\"left\"\u003eThe product kills fleas before they lay eggs and thus prevents household contamination. It can be used as part of a treatment strategy for the control of flea allergy dermatitis (FAD).\u003c\/p\u003e\n\u003cp align=\"left\"\u003eMilbemycin oxime:\u003c\/p\u003e\n\u003cp align=\"left\"\u003eMilbemycin oxime is an endectocidal antiparasitic belonging to the macrocyclic lactone group. Milbemycin oxime is a mixture of milbemycin A\u003csub\u003e4 \u003c\/sub\u003eand milbemycin A\u003csub\u003e3\u003c\/sub\u003e (in a 20:80 ratio for A\u003csub\u003e3\u003c\/sub\u003e:A\u003csub\u003e4\u003c\/sub\u003e). It is isolated from the fermentation of \u003cem\u003eStreptomyces milbemycinicus\u003c\/em\u003e.\u003c\/p\u003e\n\u003cp align=\"left\"\u003eMilbemycin oxime acts by disrupting glutamate-activated neurotransmission in invertebrates. Milbemycin oxime increases the membrane permeability of nematodes and insects to chloride ions through glutamate-gated chloride ion channels (related to GABA and glycine receptors in vertebrates).\u003c\/p\u003e\n\u003cp align=\"left\"\u003eThis leads to hyperpolarisation of the neuromuscular membrane and to the paralysis and death of the parasites.\u003c\/p\u003e\n\u003cp align=\"left\"\u003e\u003cstrong\u003ePharmacokinetic particulars\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp align=\"left\"\u003eAfoxolaner is very rapidly absorbed systemically. The absolute bioavailability obtained was 88%. The mean maximum plasma concentration (C\u003csub\u003emax\u003c\/sub\u003e) was 1822 ± 165 ng\/ml, at 2-4 hours (T\u003csub\u003emax\u003c\/sub\u003e) after a dose of 2.5 mg\/kg afoxolaner.\u003c\/p\u003e\n\u003cp\u003eThe volume of distribution of Afoxolaner in tissues is 2.6 ± 0.6 l\/kg and the clearance value is 5.0 ± 1.2 ml\/h\/kg. The half-life is approximately 2 weeks in dogs.\u003c\/p\u003e\n\u003cp align=\"left\"\u003ePlasma concentrations of Milbemycin oxime increase rapidly within the first 1-2 hours (T\u003csub\u003emax\u003c\/sub\u003e) indicating rapid absorption from the tablet. The absolute bioavailability obtained was 81% for factor A\u003csub\u003e3\u003c\/sub\u003e and 65% for A\u003csub\u003e4\u003c\/sub\u003e respectively. The mean maximum plasma concentration (C\u003csub\u003emax\u003c\/sub\u003e), after oral administration was 1.6 ± 0.4 days and 42 ± 11 ng\/ml for A\u003csub\u003e3\u003c\/sub\u003e, 3.3 ± 1.4 days and 246 ± 71 ng\/ml for A\u003csub\u003e4\u003c\/sub\u003e.\u003c\/p\u003e\n\u003cp align=\"left\"\u003eThe volume of distribution of Milbemycin oxime in tissues is 2.7 ± 0.4 and 2.6 ± 0.6 l\/kg for form A\u003csub\u003e3\u003c\/sub\u003e and A\u003csub\u003e4\u003c\/sub\u003e respectively. Both forms have a low clearance value of 75 ± 22 ml\/h\/kg for A\u003csub\u003e3\u003c\/sub\u003e and 41 ± 12 ml\/h\/kg for A\u003csub\u003e4\u003c\/sub\u003e.\u003c\/p\u003e\n\u003cp align=\"left\"\u003e\u003cstrong\u003ePHARMACEUTICAL PARTICULARS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp align=\"left\"\u003e\u003cstrong\u003eList of excipients\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eMaize starch\u003c\/li\u003e\n\u003cli\u003eSoy protein\u003c\/li\u003e\n\u003cli\u003eBraised beef flavour\u003c\/li\u003e\n\u003cli\u003ePovidone (E1201)\u003c\/li\u003e\n\u003cli\u003eMacrogol 400\u003c\/li\u003e\n\u003cli\u003eMacrogol 4000\u003c\/li\u003e\n\u003cli\u003eMacrogol 15 hydroxystearate\u003c\/li\u003e\n\u003cli\u003eGlycerol (E422)\u003c\/li\u003e\n\u003cli\u003eMedium-chain triglycerides\u003c\/li\u003e\n\u003cli\u003eCitric acid monohydrate (E330)\u003c\/li\u003e\n\u003cli\u003eButylhydroxytoluene (E321)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp align=\"left\"\u003e\u003cstrong\u003e \u003c\/strong\u003e\u003c\/p\u003e\n\u003cp align=\"left\"\u003e\u003cstrong\u003eIncompatibilities: \u003c\/strong\u003eNot applicable.\u003c\/p\u003e\n\u003cp align=\"left\"\u003e\u003cstrong\u003eShelf life: \u003c\/strong\u003eShelf life of the veterinary medicinal product as packaged for sale: 2 years\u003c\/p\u003e\n\u003cp align=\"left\"\u003e\u003cstrong\u003e \u003c\/strong\u003e\u003c\/p\u003e\n\u003cp align=\"left\"\u003e\u003cstrong\u003eSpecial precautions for storage: \u003c\/strong\u003eKeep the blister in the outer carton to protect from light.\u003c\/p\u003e\n\u003cp align=\"left\"\u003e\u003cstrong\u003eNature and composition of primary packaging\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp align=\"left\"\u003e\u003cstrong\u003e \u003c\/strong\u003eThis veterinary medicinal product is individually packed in thermoformed PVC blisters sealed on the back with aluminium foil (Aclar\/PVC\/Alu).\u003c\/p\u003e\n\u003cp align=\"left\"\u003e1 carton box containing one blister with 1, 3 and 6 chewable tablets.\u003c\/p\u003e\n\u003cp align=\"left\"\u003eNot all package sizes may be marketed.\u003c\/p\u003e\n\u003cp align=\"left\"\u003eSpecial precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products\u003c\/p\u003e\n\u003cp align=\"left\"\u003eAny unused veterinary medicinal product or waste materials derived from such products should be disposed of in accordance with local requirements.\u003c\/p\u003e\n\u003c\/div\u003e","brand":"Anima Land","offers":[{"title":"Default Title","offer_id":57394062623052,"sku":"NEX3575","price":169.13,"currency_code":"RON","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1040\/1726\/4972\/files\/Nexgard-Spectra-S-3.5-7.5-kg-3-comprimate.jpg?v=1777296730","url":"https:\/\/www.animaland.ro\/en\/products\/nexgard-spectra-s-3-5-7-5-kg-3-comprimate","provider":"Anima Land","version":"1.0","type":"link"}